ACQUISITION OF HUMAN HERPES VIRUS-8 IN INFANCY

在婴儿期获得人类疱疹病毒 8

基本信息

  • 批准号:
    7377047
  • 负责人:
  • 金额:
    $ 4.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-03-01 至 2007-02-28
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Human herpes virus 8 (HHV-8), also called Kaposi's sarcoma herpesvirus (KSHV), was first described in 1994. The viral sequences were detected in tissues of Kaposi sarcoma removed from AIDS patients. This herpes virus is most similar to Epstein-Barr virus, another human herpes pathogen. Several other diseases have subsequently been linked to HHV-8. A key issue is how and when people acquire HHV-8 infection. Many human herpesviruses are acquired in early childhood and thereafter have decades long latency period before emerging in mid to late adulthood. The goal of this proposal is to investigate HHV-8 infection in infancy and its route of transmission in neonates born in the United States. The overall goal of this project is to determine the percent of infants who contract HHV-8 infection during the first year of life. These investigators postulate that HHV-8 infection is contracted in the first year of life in more children than previously suspected. In particular, they propose that the infection may be acquired perinatally or in the first few months of life. Presumably maternal blood, secretions in the birth canal, or breast milk would transfer infectivity to the newborn. Oral epithelial cells in the infants mouth are a susceptible cell. Thereafter, the infection would be asymptomatic until late adulthood, unless the person acquired an immunosuppressive condition.
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。人类疱疹病毒8(HHV-8),也称为卡波西肉瘤疱疹病毒(KSHV),于1994年首次被描述。从AIDS患者的Kaposi肉瘤组织中检测到病毒序列。这种疱疹病毒与另一种人类疱疹病原体爱泼斯坦-巴尔病毒最相似。随后,其他几种疾病也与HHV-8有关。一个关键问题是人们如何以及何时获得HHV-8感染。许多人类疱疹病毒在儿童早期获得,此后在成年中后期出现之前有数十年的潜伏期。该提案的目的是调查婴儿期HHV-8感染及其在美国出生的新生儿中的传播途径。该项目的总体目标是确定在生命的第一年内感染HHV-8的婴儿的百分比。这些研究人员假设,在出生后第一年感染HHV-8的儿童数量比之前怀疑的要多。特别是,他们提出感染可能是在围产期或出生后的头几个月获得的。据推测,母亲的血液、产道中的分泌物或母乳会将传染性传给新生儿。婴幼儿口腔上皮细胞是一种易感细胞。此后,感染将无症状,直到成年后期,除非该人获得免疫抑制条件。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ERICK B GERDAY其他文献

ERICK B GERDAY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ERICK B GERDAY', 18)}}的其他基金

ACQUISITION OF HUMAN HERPES VIRUS-8 IN INFANCY
在婴儿期获得人类疱疹病毒 8
  • 批准号:
    7201380
  • 财政年份:
    2005
  • 资助金额:
    $ 4.31万
  • 项目类别:

相似国自然基金

靶向Human ZAG蛋白的降糖小分子化合物筛选以及疗效观察
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
HBV S-Human ESPL1融合基因在慢性乙型肝炎发病进程中的分子机制研究
  • 批准号:
    81960115
  • 批准年份:
    2019
  • 资助金额:
    34.0 万元
  • 项目类别:
    地区科学基金项目
基于自适应表面肌电模型的下肢康复机器人“Human-in-Loop”控制研究
  • 批准号:
    61005070
  • 批准年份:
    2010
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development of oncolytic virus therapy for human sarcomas using midkine promoter-regulated oncolytic herpes simplex virus type 1
使用中期因子启动子调节的溶瘤单纯疱疹病毒 1 型开发针对人类肉瘤的溶瘤病毒疗法
  • 批准号:
    20K16392
  • 财政年份:
    2020
  • 资助金额:
    $ 4.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Control of herpes simplex virus type 1 specific replication and transmission mechanisms in human dendritic cells
人类树突状细胞中1型单纯疱疹病毒特异性复制和传播机制的控制
  • 批准号:
    398064017
  • 财政年份:
    2018
  • 资助金额:
    $ 4.31万
  • 项目类别:
    Research Grants
Development of oncolytic virus therapy with a third-generation oncolytic herpes simplex virus type 1 for human sarcoma
开发用于治疗人类肉瘤的第三代溶瘤单纯疱疹病毒 1 型溶瘤病毒疗法
  • 批准号:
    19K21290
  • 财政年份:
    2018
  • 资助金额:
    $ 4.31万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Human Herpes Virus 6 reactivation after allogeneic stem cell transplantation
同种异体干细胞移植后人类疱疹病毒6重新激活
  • 批准号:
    17K09961
  • 财政年份:
    2017
  • 资助金额:
    $ 4.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
DEVELOPMENT OF A NOVEL ANTIVIRAL TO TREAT AND PREVENT ACYCLOVIR RESISTANCE IN HUMAN OCULAR HERPES KERATITIS
开发一种新型抗病毒药物来治疗和预防人眼疱疹性角膜炎的阿昔洛韦耐药性
  • 批准号:
    9255235
  • 财政年份:
    2017
  • 资助金额:
    $ 4.31万
  • 项目类别:
A therapeutic strategy for human hepatocellular carcinoma using "armed" oncolytic herpes simplex viruses.
使用“武装”溶瘤单纯疱疹病毒治疗人类肝细胞癌的策略。
  • 批准号:
    17K18252
  • 财政年份:
    2017
  • 资助金额:
    $ 4.31万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Identification of reactivation factors for human herpes viruses
人类疱疹病毒再激活因子的鉴定
  • 批准号:
    15K09591
  • 财政年份:
    2015
  • 资助金额:
    $ 4.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of CD134 expression on T cell in febrile infants with primary human herpes virus 6B infection
原发性人疱疹病毒6B感染发热婴儿T细胞CD134表达分析
  • 批准号:
    15K19613
  • 财政年份:
    2015
  • 资助金额:
    $ 4.31万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Development of Novel Human Herpes Virus Inhibitors
新型人类疱疹病毒抑制剂的开发
  • 批准号:
    8826586
  • 财政年份:
    2014
  • 资助金额:
    $ 4.31万
  • 项目类别:
Development of Novel Human Herpes Virus Inhibitors
新型人类疱疹病毒抑制剂的开发
  • 批准号:
    8718303
  • 财政年份:
    2014
  • 资助金额:
    $ 4.31万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了